Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV Infection
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Sep 2015
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
- 18 Oct 2014 New trial record